retatrutide triple agonist A review of an investigational drug retatrutide, a novel agent for the treatment of obesity | European Journal of Clinical Pharmacology Retatrutide Obesity Triple Agonist Targeting

It mimics a natural hormone in the body called GLP-1 (glucagon-like peptide-1), which helps regulate hunger and blood sugar

Tirzepatide users were less likely to experience any major cardiovascular problems following surgery than people not on the drug (roughly 30% lower risk), though the rate of some problems like heart attacks remained roughly the same between the two groups

While genetic testing does not predict exact medication response, it can provide clinical context showing why your provider considers GLP-1 appropriate for your specific metabolic profile

A microdose tirzepatide schedule might use 1 to 2.5 mg weekly instead of the standard 5 to 15 mg range

Social interactions may function in part to build cognitive reserve, which confers resilience even in the presence of brain pathologies (Xu et al., 2019)